HARVARD BIOSCIENCE INC
For the period ended Dec 31, 2023. Filed Mar 7, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 7, 2024
HBIO$9.09+8.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| HARVARD BIOSCIENCE, INC. | ||
|---|---|---|
| CONSOLIDATED STATEMENTS OF OPERATIONS | ||
| (In thousands, except per share data) | ||
| Year Ended December 31, | ||
| 2023 | 2022 | |
| Revenues | $112,250 | $113,335 |
| Cost of revenues | 46,179 | 52,516 |
| Gross profit | 66,071 | 60,819 |
| Sales and marketing expenses | 24,108 | 25,041 |
| General and administrative expenses | 22,780 | 24,493 |
| Research and development expenses | 11,764 | 12,329 |
| Amortization of intangible assets | 5,525 | 6,122 |
| Litigation settlement - Note 16 | - | (233) |
| Total operating expenses | 64,177 | 67,752 |
| Operating income (loss) | 1,894 | (6,933) |
| Other (expense) income: | ||
| Interest expense | (3,591) | (2,548) |
| Unrealized loss on equity securities - Note 16 | (632) | - |
| Other (expense) income, net | (227) | 302 |
| Total other expense | (4,450) | (2,246) |
| Loss before income taxes | (2,556) | (9,179) |
| Income tax expense | 859 | 337 |
| Net loss | $(3,415) | $(9,516) |
| Loss per share: | ||
| Basic and diluted loss per share | $(0.08) | $(0.23) |
| Weighted-average common shares: | ||
| Basic and diluted | 42,420 | 41,413 |
See accompanying notes to condensed consolidated financial statements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.